公开(公告)号：US20220233682A1

公开(公告)日：2022-07-28

申请号：US17573806

申请日：2022-01-12

Applicant: Variation Biotechnologies Inc.

Inventor： David Evander Anderson ,  Anne-Catherine Fluckiger

IPC: A61K39/215 ,  A61K39/21 ,  A61K39/205 ,  A61K39/39 ,  A61P31/14

Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include a spike protein from the Beta variant of SARS-Cov-2.

公开(公告)号：US11253587B2

公开(公告)日：2022-02-22

申请号：US17218148

申请日：2021-03-30

Applicant: Variation Biotechnologies Inc.

Inventor： David Evander Anderson ,  Anne-Catherine Fluckiger

IPC: A61K39/12 ,  A61K39/00 ,  C12N7/00 ,  C07K14/005 ,  A61K39/21 ,  A61K39/215

Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.

公开(公告)号：US20210353741A1

公开(公告)日：2021-11-18

申请号：US17218148

申请日：2021-03-30

Applicant: Variation Biotechnologies Inc.

Inventor： David Evander Anderson ,  Anne-Catherine Fluckiger

IPC: A61K39/215 ,  C12N7/00

Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.

公开(公告)号：US20240123060A1

公开(公告)日：2024-04-18

申请号：US17621033

申请日：2020-06-19

Applicant: Variation Biotechnologies Inc. ,  Brii Biosciences Limited

Inventor： David Evander Anderson ,  Zhi Hong ,  Qing Zhu

IPC: A61K39/29 ,  A61K38/21 ,  A61K39/39 ,  A61P31/20 ,  A61P37/04

CPC classification number: A61K39/292 ,  A61K38/212 ,  A61K39/39 ,  A61P31/20 ,  A61P37/04 ,  A61K2039/55505

Abstract: The present disclosure provides compositions and methods useful for inducing an immune response and overcoming immune tolerance in a subject suffering from Hepatitis B. As described herein, the compositions of the disclosure comprise HBsAg having S, Pre-S1 and Pre-S2 proteins, an aluminum phosphate adjuvant and interferon-α.

公开(公告)号：US20200376113A1

公开(公告)日：2020-12-03

申请号：US16888398

申请日：2020-05-29

Applicant: Variation Biotechnologies Inc.

Inventor： David Evander Anderson

IPC: A61K39/245 ,  C07K14/005 ,  A61P35/00 ,  C12N7/00

Abstract: The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM), e.g., compositions comprising virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with GM-CSF, which, at dose of at least 10 μg gB/pp65Gag, reverse dysregulation of anti-HCMV immunity in GBM patients.

公开(公告)号：US12128100B2

公开(公告)日：2024-10-29

申请号：US17293431

申请日：2019-11-13

Applicant: Variation Biotechnologies Inc.

Inventor： David Evander Anderson ,  Tanvir Ahmed

IPC: A61K39/00 ,  A61K38/21 ,  A61K39/12 ,  A61K39/29 ,  A61K45/06 ,  A61P31/20 ,  A61P37/04 ,  A61P43/00

CPC classification number: A61K39/292 ,  A61K45/06 ,  A61P31/20 ,  A61P37/04 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/57

Abstract: The present disclosure provides compositions and methods useful for inducing a The cell response in a subject suffering from Hepatitis B. As described herein, the compositions of the disclosure comprise HBsAg having S, Pre-S1 and Pre-S2 proteins and an aluminum phosphate adjuvant. In a preferred embodiment, the immunogenic composition comprises at least 20 μg/ml of HBsAg antigen and the amount of non-adsorbed antigen is at least 30%.